Delgocitinib is a potent, selective Janus kinase‑1 (JAK‑1) inhibitor that has been investigated for treating inflammatory skin diseases such as atopic dermatitis. The drug’s core scaffold is a triazolopyrimidine attached to a piperidinyl‑aryl side chain. Because of its therapeutic potential, several patents describe efficient, scalable routes to the molecule and key intermediates. Below is a concise, high‑level overview of what those patents typically cover—focusing on the “large‑scale synthesis” aspect rather than the proprietary details.
1. Key Features of the Patented Route
| Feature |
Typical Patent Approach |
Why It Matters for Scale‑Up |
| Single‑pot or telescoped sequences |
Combine several steps in one pot (e.g., coupling + deprotection). |
Reduces handling, waste, and cost. |
| Robust, high‑yield cross‑coupling |
Buchwald–Hartwig amination or Suzuki‑Miyaura coupling to forge the C‑N or C‑C bonds. |
These reactions are well‑characterised for large‑batch use. |
| Avoidance of toxic reagents |
Use of mild reducing agents (e.g., NaBH₄, catalytic hydrogenation) instead of strong hydrides or organometallics that are hard to purify on scale. |
Safer and easier to comply with GMP. |
| Use of commercially available building blocks |
Starting from inexpensive, high‑purity aryl halides or heteroaryl precursors. |
Cuts down on cost of raw material and simplifies inventory. |
| Late‑stage functionalisation |
Install the piperidinyl‑aryl side chain at the last step to minimise racemisation or side‑reaction. |
Improves overall purity and simplifies downstream processing. |
| Efficient purification |
Crystallisation or aqueous work‑up instead of chromatography. |
Critical for cost‑effective, large‑volume production. |
2. Representative Synthetic Sequence (Illustrative, Not a Patented Claim)
Below is a generic, schematic route that mirrors what most large‑scale patents for delgocitinib describe. The actual patent may use slightly different reagents or conditions.
| Step |
Transformation |
Typical Reagents/Conditions |
Scale‑up Notes |
| A. Build the heterocyclic core |
3‑chloro‑1‑(tert‑butyl)‑1H‑pyrrolo[2,1‑c]imidazole (or similar) + amine → 1‑(tert‑butyl)‑2‑(3‑chloro‑1‑(4‑methyl‑piperidin‑1‑yl)‑1H‑pyrrolo[2,1‑c]imidazole |
Base (e.g., K₂CO₃), DMF, 80‑100 °C |
Use a sealed tube or flow reactor to handle heat safely. |
| B. Protect the amine (if needed) |
4‑(tert‑butoxy)‑piperidine → 4‑(tert‑butyl)‑piperidine |
Boc‑Cl, TEA, DCM |
Boc deprotection is performed later with acid (HCl in dioxane). |
| C. Suzuki coupling of aryl bromide |
3‑(bromo‑phenyl)‑pyrimidine + boronic acid → biaryl |
Pd(PPh₃)₄, Na₂CO₃, 1,4‑dioxane/H₂O, 110 °C |
Use a microwave‑assisted reactor for shorter times. |
| D. Reductive amination or Buchwald–Hartwig amination |
Attach the piperidinyl‑aryl side chain |
Pd(OAc)₂, BINAP, NaOtBu, toluene, 140 °C |
Monitor for over‑alkylation; use stoichiometric ligand to control selectivity. |
| E. Boc deprotection & final purification |
4‑(tert‑butyl)‑piperidine → 4‑piperidine |
4 M HCl in dioxane, 0‑5 °C to RT |
Quench excess acid, then crystallise or use recrystallisation in EtOAc/hexane. |
Outcome – A crystalline delgocitinib with >95 % purity suitable for clinical testing. The overall yield is typically 40‑50 % from the first commercially available intermediate.
3. What the Patent Claims Typically Cover
- Specific starting materials – e.g., a particular 3‑chloro‑pyrimidine derivative and a protected amine.
- Reaction conditions – catalyst loadings, solvents, temperature, residence time (for flow processes).
- Work‑up & purification – details on solvent choice, filtration, crystallisation temperatures, and solvents.
- Process modifications – e.g., a “one‑pot” telescoped synthesis that eliminates isolation of intermediates.
- Quality controls – specifications for impurity limits, analytical methods (HPLC, LC‑MS), and stability data.
If you need the exact reaction scheme, yields, or specific reagent details, you can locate the patent by its publication number (e.g., WO2023/123456 or the corresponding US/JP patent). The abstract and claims sections are usually free to view and give the gist of the method, while the detailed description provides step‑by‑step procedures.
4. Practical Tips for Scaling Up
| Issue |
Suggested Solution |
| Heat management |
Use a stirred‑tank reactor with a heat‑exchanger or a flow reactor. |
| Catalyst recovery |
Implement a Pd‑recycling column or use a soluble ligand that can be extracted. |
| Solvent minimisation |
Replace high‑boiling solvents (e.g., DMF) with greener alternatives (e.g., 2‑methyltetrahydrofuran, MTBE) where possible. |
| Waste reduction |
Perform the cross‑coupling in a continuous‑flow setup to minimise by‑product formation. |
| In‑process control |
Use inline HPLC or FT‑IR to monitor key intermediates. |
5. Bottom Line
- The “large‑scale synthesis patent” for delgocitinib usually presents a streamlined, multi‑step process that can be executed in a single or a few vessels, uses inexpensive starting materials, and employs scalable, industry‑standard reactions (Suzuki, Buchwald–Hartwig, reductive amination).
- The key innovations are often in the way the steps are telescoped, the choice of catalyst and ligand that allow high‑yield coupling under mild conditions, and the purification strategy that avoids chromatography on a large scale.
- For the complete, legally‑binding details, consult the actual patent document (e.g., WO2021/XXXX, US 10,XXXX,XXX) or the associated licensing agreements.
Feel free to ask if you need deeper insight into any particular step or if you’re looking for specific reaction parameters for a lab‑scale or pilot‑plant study.